Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors

Journal of Clinical Investigation

Volumn 99, Issue 8, 1997, Pages 1926-1935

  Liu, Yun He ^a   Yang, Xiao Ping ^a   Sharov, Victor G ^b   Nass, Omar ^b   Sabbah, Hani N ^b   Peterson, Edward ^a   Carretero, Oscar A ^a  

^a HENRY FORD HOSPITAL   (United States)

^b Heart and Vascular Institute   (United States)

Author keywords

angiotensin II type 1 and 2 receptors; angiotensin converting enzyme; chronic heart failure; kinin antagonist; kinins

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; RAMIPRIL;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031003230     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119360     Document Type: Article

References (66)

1. Gavras, H., D.P. Faxon, J. Berkoben, H.R. Brunner, and T.J. Ryan. 1978. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 58:770-776.
2. The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316:1429-1435.
3. Pfeffer, M.A., E. Braunwald, L.A. Moyé, L. Basta, E.J. Brown, Jr., T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327:669-677.
4. The SOLVD Investigators. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327:685-691.
5. Acute Infarction Ramipril Efficacy (AIRE) study investigators. 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:821-828.
6. Gavras, H., and I. Gavras. 1991. Cardioprotective potential of angiotensin converting enzyme inhibitors. J. Hypertens. 9:385-392.
7. Garg, R., and S. Yusuf, for the Collaborative Group on ACE Inhibitor Trials. 1995. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [review]. J. Am. Med. Assoc. 273:1450-1456.
8. Carretero, O.A., and A.C. Scicli. 1995. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In Hypertension: Physiology, Diagnosis, and Management. J.H. Laragh and B.M. Brenner, editors. Raven Press, New York. 983-999.
9. Gavras, I., A. Manolis, and H. Gavras. 1995. Effects of ACE inhibition on the heart. J. Hum. Hypertens. 9:455-458.
10. Carretero, O.A., A.G. Scicli, and S.R. Maitra. 1981. Role of kinins in the pharmacological effects of converting enzyme inhibitors. In Angiotensin Converting Enzyme Inhibitors. Mechanisms of Action and Clinical Implications. Z.P. Horovitz, editor. Urban & Schwarzenberg, Baltimore. 105-121.
11. Linz, W., and B.A. Schölkens. 1992. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 20 (Suppl. 9):S83-S90.
12. Liu, Y.-H., X.-P. Yang, V.G. Sharov, D.H. Sigmon, H.N. Sabbah, and O.A. Carretero. 1996. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension (Dallas). 27:7-13.
13. Farhy, R.D., O.A. Carretero, K.-L. Ho, and A.G. Scicli. 1993. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ. Res. 72:1202-1210.
14. Hartman, J.C., T.M. Wall, T.G. Hullinger, and R.J. Shebuski, 1993. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J. Cardiovasc. Pharmacol. 21:996-1003.
15. Abassi, Z.A., G. Kelly, E. Golomb, H. Klein, and H.R. Keiser. 1994. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J. Pharmacol. Exp. Ther. 268:224-230.
16. Dickstein, K., P. Chang, R. Willenheimer, S. Haunso, J. Remes, C. Hall, and J. Kjekshus. 1995. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J. Am. Coll. Cardiol. 26:438-445.
17. Dickstein, K., S. Gottlieb, E. Fleck, J. Kostis, B. Levine, M. DeKock, and T. LeJemtel. 1994. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J. Hypertens. (Suppl.) 12:S31-S35.
18. Gottlieb, S.S., K. Dickstein, E. Fleck, J. Kostis, T.B. Levine, T. LeJemtel, and M. DeKock. 1993. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 88:1602-1609.
19. Whitebread, S., M. Mele, B. Kamber, and M. de Gasparo. 1989. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 163:284-291.
20. Campbell, D.J., A. Kladis, and A.J. Valentijn. 1995. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J. Cardiovasc. Pharmacol. 26:233-240.
21. 1 receptor: gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. USA. 92: 10663-10667.
22. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 95:651-657.
23. 2 production in conscious rats. J. Clin. Invest. 97: 1978-1982.
24. Seyedi, N., X. Xu, A. Nasjletti, and T.H. Hintze. 1995. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension (Dallas). 26:164-170.
25. Liu, Y.-H., X.-P. Yang, O. Nass, H.N. Sabbah, E. Peterson, and O.A. Carretero. 1997. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am. J. Physiol. 272:H722-H727.
26. Yang, X.-P., H.N. Sabbah, Y.-H. Liu, V.G. Sharov, E.J. Mascha, I. Alwan, and O.A. Carretero. 1993. Ventriculographic evaluation in three rat models of cardiac dysfunction. Am. J. Physiol. 266:H1946-H1952.
27. Yang, S.S., L.G. Bentivoglio, V. Maranhao, and H. Goldberg. 1978. Cardiac volume. In From Cardiac Catheterization Data to Hemodynamic Parameters. S.S. Yang, editor. F.A. Davis, Philadelphia. 101-151.
28. Hansen-Smith, F.M., L. Watson, D.Y. Lu, and I. Goldstein. 1988. Griffonia simplicifolia I: fluorescent tracer for microcirculatory vessels in nonperfused thin muscles and sectioned muscle. Microvasc. Res. 36:199-215.
29. Laitinen, L. 1987. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem. J. 19:225-234.
30. Rakušan, K. 1971. Changes in the myocardial oxygen tension caused by changes in several oxygen determinants, with special consideration of the diffusion distance. In Oxygen in the Heart Muscle. Charles C. Thomas Publisher. Springfield, Ill. 66-71.
31. Carini, D.J., J.V. Duncia, P.E. Aldrich, A.L. Chiu, A.L. Johnson, M.E. Pierce, W.A. Price, J.B. Santella III, G.J. Wells, R.R. Wexler, et al. 1991. Non-peptide angiotensin 11 receptor antagonists: the discovery of a series of N-(biphenylylmethyl) imidazoles as potent, orally active antihypertensives. J. Med. Chem. 34:2525-2547.
32. Linz, W., G. Wiemer, and B.A. Schölkens. 1993. Bradykinin prevents left ventricular hypertrophy in rats. J. Hypertens. 11 (Suppl. 5):S96-S97.
33. Rhaleb, N.-E., X.-P. Yang, A.G. Scicli, and O.A. Carretero. 1994. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension (Dallas). 23:865-868.
34. Gohlke, P., W. Linz, B.A. Schölkens, I. Kuwer, S. Bartenhach, A. Schnell, and T. Unger. 1994. Angiotensin converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension (Dallas). 23:411-418.
35. McDonald, K.M., J. Mock, A. D'Aloia, T. Parrish, K. Hauer, G. Francis, A. Stillman, and J.N. Cohn. 1995. Bradykinin antagonism inhibits the anti-growth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 91:2043-2048.
36. McDonald, K.M., M. Garr, P.P. Carlyle, G.S. Francis, K. Hauer, D.W. Hunter, T. Parish, A. Stillman, and J.N. Cohn. 1994. Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 90:3034-3046.
37. Stauss, H.M., Y.-C. Zhu, T. Redlich, D. Adamiak, A. Molt, K.C. Kregel, and T. Unger. 1994. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J. Cardiovasc. Risk. 1: 255-262.
38. Fletcher, P.J., J.M. Pfeffer, M.A. Pfeffer, and E. Braunwald. 1981. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ. Res. 49:618-626.
39. 2-receptor subtypes in hypertrophied rat hearts. Am. J. Physiol. 267:H844-H852.
40. 2+. Am. J. Physiol. 259:F269-F278.
41. Everett, A.D., A. Tufro-McReddie, A. Fisher, and R.A. Gomez. 1994. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertention (Dallas). 23:587-592.
42. Nio, Y., H. Matsubara, S. Murasawa, M. Kanasaki, and M. Inada. 1995. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 95:46-54.
43. Suzuki, J., H. Matsubara, M. Urakami, and M. Inada. 1993. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ. Res. 73:439-447.
44. Ichiki, T., P.A. Labosky, C. Shiota, S. Okuyama, Y. Imagawa, A. Fogo, F. Niimura, I. Ichikawa, B.L. Hogan, and T. Inagami. 1995. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature (Lond). 377:748-750.
45. Hecker, M., I. Porsti, and R. Busse. 1994. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors. Braz. J. Med. Biol. Res. 27:1917-1921.
46. Seyedi, N., X. Xu, A. Nasjletti, and T.H. Hintze. 1995. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension (Dallas). 26:164-170.
47. Brosnihan, K.B., P. Li, and C.M. Ferrario. 1996. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension (Dallas). 27:523-528.
48. Tomiyama, H., A.G. Scicli, G.M. Scicli, and O.A. Carretero. 1990. Renal effects of Fab fragments of kinin antibodies on deoxycorticosterone acetate-salt-treated rats. Hypertension (Dallas). 15:761-766.
49. 2, water, and sodium excretion. Hypertension (Dallas). 25:1008-1013.
50. Lo, M., K.-L. Liu, P. Lantelme, and J. Sassard. 1995. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J. Clin. Invest. 95:1394-1397.
51. Dahlöf, B. 1992. Regression of left ventricular hypertrophy - are there differences between antihypertensive agents? Cardiology. 81:307-315.
52. Liebson, P.R., G.A. Grandits, S. Dianzumba, R.J. Prineas, R.H. Grimm, Jr., J.D. Neaton, and J. Stamler, for the Treatment of Hypertension Study Research Group. 1995. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 91:698-706.
53. Sharpe, N., J. Murphy, H. Smith, and S. Hannan. 1990. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction. Eur. Heart J. 11 (Suppl. B):147-156.
54. Nolly, H., L.A. Carbini, G. Scicli, O.A. Carretero, and A.G. Scicli. 1994. A local kallikrein-kinin system is present in rat hearts. Hypertension (Dallas). 23:919-923.
55. Nolly, H., O.A. Carretero, and A.G. Scicli. 1993. Kallikrein release by vascular tissue. Am. J. Physiol. 265:H1209-H1214.
56. van Gilst, W.H., R.A. Tio, J. van Wijngaarden, P.A. de Graeff, and H. Wesseling. 1992. Effects of converting enzyme inhibitors on coronary flow and myocardial ischemia. J. Cardiovasc. Pharmacol. 19 (Suppl. 5):S134-S139.
57. 9-bradykinin release following reperfusion of the ischaemic rat heart. Br. J. Pharmacol. 115:476-478.
58. Campbell, D.J., A. Kladis, and A.-M. Duncan. 1994. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension (Dallas). 23:439-449.
59. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ. Res. 76:773-780.
60. Lindpaintner, K., and D. Ganten. 1991. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ. Res. 68:905-921.
61. Dzau, V.J., and R.N. Re. 1987. Evidence for the existence of renin in the heart. Circulation. 75 (Suppl. 1):I-134-I-136.
62. Sadoshima, J., Y. Xu, H.S. Slayter, and S. Izumo. 1993. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:977-984.
63. 1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am. J. Physiol. 258: H806-H813.
64. Baker, K.M., and J.F. Aceto. 1990. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am. J. Physiol. 259:H610-H618.
65. von Lutterotti, N., D.F. Catanzaro, J.E. Sealey, and J.H. Laragh. 1994. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation. 89:458-470.
66. Cohn, J.N. 1995. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition [editorial]. Circulation. 91:2504-2507.